||Saxagliptin is a selective and reversible DPP4 inhibitor (IC50: 26 nM; Ki: 1.3 nM).
||Linagliptin is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity.
||Sitagliptin, a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination wit
||Evogliptin tartrate has potential for anti-atherosclerosis therapy that targets arterial inflammation. Evogliptin tartrate is a potent, orally bioavailable and selective dipeptidy
||Retagliptin Phosphate is pharmaceutical composition of DPP-4 inhibitor, for treating type-2 diabetes.
||3-Pyridylacetic acid hydrochloride
||3-Pyridylacetic acid hydrochloride is an organic compund.
||Vildagliptin is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydroly
||Picolamine acts as a potential inhibitor of DPP-4.
||Trelagliptin(SYR-472) is a long-acting inhibitor of dipeptidyl peptidase-4 (DPP-4), being developed for the treatment of type 2 diabetes (T2D).
||Omarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.
||Alogliptin Benzoate(SYR 322), an effective and specific DPP-4 inhibitor (IC50<10 nM), exhibits greater than 10, 000-fold selectivity over DPP-8/9. Alogliptin may inhibit inflammato
||Talabostat mesylate is an orally active, selective inhibitor of dipeptidyl peptidases IV (DPP4, IC50: 0.18 nM), including tumor-associated fibroblast activation protein. This agent
||Alogliptin(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10, 000-fold selectivity over DPP-8 and DPP-9.
||Saxagliptin is a selective and reversible DPP4 inhibitor with IC50 of 26 nM.
||Trelagliptin is a highly specific and long-acting DPP-4 inhibitor.
||Teneligliptin is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC
||Anagliptin is a potent Inhibitor of DPP-4(IC50 of 3.8 nM), for the treatment of type 2 diabetes mellitus.
||Gemigliptin is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor(KD : 7.25 nM.)